The Europe Molecular Diagnostic Market for the period 2016-2021 is expected to account for USD XX billion at a CAGR of XX% from USD XX billion on 2016. Molecular or Nucleic acids based diagnosis of human disorders is referred to as the detections of the various pathogenic mutations in DNA or RNA samples which help us in the process of detection, diagnosis, treatment, prognosis and monitoring response to the therapy.
Molecular diagnostics combines laboratory medicine with the technology and knowledge of molecular genetics and has been enormously revolutionized over the past decades, benefiting from the discoveries in the field of molecular biology. Molecular diagnostics has found a wide application in the detection of infectious and non infectious disease like cancer and has been a major technological revolution for diagnostics in hospital and academic laboratories.
The European Molecular Diagnostic have been driven by a number of factors like increase in the number of infectious and non infectious diseases, technological advancement in microarray, PCR and other technologies, the rapid growth in genomic and proteomic research and the availability of funds specially from the European Commission for molecular diagnostic research. However, the market is restrained by the lack of skilled personnel to handle complex technology, complex regulatory network and government policies and the high cost of the technology.
The European molecular diagnostic market can be segmented based on the technology, products and services, application and end users. Based on technology, the market is segmented into hybridization (ISH, FISH), microarray, DNA sequencing (Capillary electrophoresis, NGS), PCR based methods (cold start PCR, Real time PCR, Reverse Transcriptase PCR, others), Isothermal Nucleic Acid Amplification Technology and Molecular Imaging. Based on products and services, the market is segmented into instruments, reagents, software and services. Based on application, the market is segmented into infectious diseases, cancer, genetic testing, new born screening, blood screening, microbiology and others. Based, on end users the market is segmented as hospitals, academic and research laboratories and others.
Based on geographical location, the Europe molecular diagnostic market can be broadly divided into France, UK, Germany, Spain, Portugal, Scandinavia and Italy.
The current genomic revolution, the fast and accurate quantification at point of care and increase in the number of biomarkers that are in the pipeline research are some of the market opportunities for the key market players. However, they face the challenge of the lack of awareness about the technology among many people and the technology being restricted only to the urban areas of Europe. The key players in the market are Affymetrix, Agilent Technologies, Roche Diagnostics, Bio-Rad Laboratories, Inc, Qiagen N.V. among many others.
Key Deliverables in the Study